Peptide Regulation in 2026: What Changed for Publishers
Peptide Regulation in 2026: What Changed for Publishers

In 2026, FDA removed 12 peptides from its Category 2 "safety risk" list (April) and an FDA advisory committee recommended six peptides, including BPC-157, for the 503A bulks list (July). Neither step approved any peptide. On October 30, 2026, HHS published a draft interim policy on compounding six of them under strict conditions, but none is FDA-approved and FDA must still complete rulemaking. Last verified November 3, 2026.
This update summarizes what happened, what it means, and how to describe it accurately. We'll add dated notes as FDA acts, rather than rewriting history.
The short version
| Date | What happened | What it means |
|---|---|---|
| April 15, 2026 | FDA announced removal of 12 peptides from Category 2 of the 503A bulks list | No longer flagged for significant safety risk, but not eligible to compound by that change alone |
| July 23–24, 2026 | FDA's Pharmacy Compounding Advisory Committee voted on seven peptides | Recommended six for the bulks list; voted against one. Nonbinding |
| October 30, 2026 | HHS published a draft interim enforcement-discretion policy for six peptides | Draft and nonbinding; comments due November 13; not approval |
| Next | Second advisory meeting planned before end of February 2027 | More changes likely |
April 2026: removal of 12 peptides from Category 2
Category 2 lists bulk substances FDA flagged as raising significant safety risks. Removing a substance means FDA no longer treats it as flagged, but it doesn't place it in Category 1, where FDA exercises enforcement discretion for compounding. Legal analysts describe these peptides, including BPC-157, as sitting in a gray area (Orrick).
July 2026: advisory committee votes
FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and Epitalon.
- Recommended for the bulks list: BPC-157, KPV and TB-500 (8–6, one abstention), MOTS-c (7–5, two abstentions), and Semax and Epitalon by similarly narrow margins.
- Not recommended: emideltide (7–6, one abstention).
The votes are advisory. FDA must decide whether to accept them and complete notice-and-comment rulemaking before any of them joins the list (AJMC).
October 2026: HHS draft interim policy
FDA removed 12 peptides from its Category 2 safety-risk list in April 2026, and in July an FDA advisory committee recommended six peptides for the 503A bulks list. On October 30, 2026, HHS published a draft interim enforcement-discretion policy for those six: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. HHS says it doesn't intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound them, but only under strict conditions. Those include a patient-specific prescription, a single active ingredient, a registered and tested ingredient source, approved routes for each peptide, adverse-event reporting, and a "compounded drug product, not for resale" label. Outsourcing facilities (503B) aren't covered. The policy isn't binding, isn't FDA approval, doesn't add any peptide to the bulks list, doesn't cover "research use only" products and doesn't override state pharmacy rules. It says nothing about advertising. Comments are open until November 13, 2026, and HHS can revise it. FDA rulemaking is still required. (Federal Register)
What has not changed
- None of these peptides is an FDA-approved drug.
- None has been added to the 503A bulks list yet.
- HHS's interim policy (October 30, 2026) is a draft about enforcement discretion, not approval. It doesn't cover "research use only" products or 503B outsourcing facilities.
- "Research use only" products remain unapproved for human use.
- Compounded drugs still aren't FDA-approved.
What to watch next
- Whether FDA accepts the committee's recommendations.
- Any proposed rule, its comment period and the final rule.
- Whether HHS revises its draft policy after comments close on November 13, 2026, and any FDA proposed rule adding these peptides to the 503A bulks list.
- The second advisory committee meeting, planned before the end of February 2027.
Live status: we track each of these items, with dates and sources, on the telehealth regulation tracker.
How to word regulatory status in your content
| Instead of | Write |
|---|---|
| "FDA approved BPC-157" | "An FDA advisory committee recommended BPC-157 for the compounding list in July 2026; FDA hasn't finalized a rule." |
| "Peptides are now legal" | "Under a draft interim HHS policy (October 2026), HHS says it doesn't intend to act against licensed pharmacies compounding six peptides for individual patients under strict conditions; none is FDA-approved." |
| "BPC-157 is safe" | Remove. Don't make safety claims. |
Always add the date you verified the status, and link to a primary source.
Frequently asked questions
Did FDA approve BPC-157?
No. An FDA advisory committee recommended adding it to the 503A bulks list in July 2026. That's a nonbinding recommendation, and BPC-157 isn't an FDA-approved drug.
What does removal from Category 2 mean?
FDA no longer flags the substance as a significant safety risk. It doesn't make the substance eligible for compounding.
When will the rules be final?
Not yet known. FDA has to decide on the recommendations and complete rulemaking, which typically includes a public comment period. In the meantime, HHS published a draft interim policy on October 30, 2026, covering limited compounding of six peptides.
How should I describe a pending rule?
Say what happened, when, and that it isn't final, with a link to a primary source and the date you checked.
Practical guides and programs for health and beauty publishers.
Educational content for marketers and publishers, not medical, legal or financial advice. Examples labeled hypothetical are illustrations, not results. MarketHealth may earn revenue from programs it describes. See our affiliate disclosure and editorial policy.

